Sanofi Wins Control of Genzyme

Feb. 16, 2011
Sanofi-Aventis will pay $20.1 billion for Genzyme

French pharmaceutical giant Sanofi-Aventis on Feb. 16 won control of giant U.S. biotechnology group Genzyme after increasing its offer considerably in a drawn out battle.

Sanofi-Aventis will pay $20.1 billion for Genzyme, with a further payment of $3.8 billion depending on how the U.S. company performs, the two companies said in a statement.

The two boards unanimously approved the deal and hope to close at the beginning of the second quarter, they said.

Sanofi-Aventis initially offered $18.5 million or $69 per share in October last year after talks on a tie-up with Genzyme made no progress.

At $20.1 billion, or $74 per share, the deal is second only to Roche's acquisition of another US firm, Genentech for $46.8 billion in 2009.

Copyright Agence France-Presse, 2011

Popular Sponsored Recommendations

Empowering the Modern Workforce: The Power of Connected Worker Technologies

March 1, 2024
Explore real-world strategies to boost worker safety, collaboration, training, and productivity in manufacturing. Emphasizing Industry 4.0, we'll discuss digitalization and automation...

3 Best Practices to Create a Product-Centric Competitive Advantage with PRO.FILE PLM

Jan. 25, 2024
Gain insight on best practices and strategies you need to accelerate engineering change management and reduce time to market. Register now for your opportunity to accelerate your...

How Manufacturers Can Optimize Operations with Weather Intelligence

Nov. 2, 2023
The bad news? Severe weather has emerged as one of the biggest threats to continuity and safety in manufacturing. The good news? The intelligence solutions that build weather ...

Transformative Capabilities for XaaS Models in Manufacturing

Feb. 14, 2024
The manufacturing sector is undergoing a pivotal shift toward "servitization," or enhancing product offerings with services and embracing a subscription model. This transition...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!